Sequenom, Illumina Team Up on Down Syndrome Test


A noninvasive diagnostic test for fetal Down syndrome is the hoped-for outcome a deal announced today under which Sequenom, the genetic testing vendor, will obtain tools from Illumina, which develops large-scale systems for genetic analysis. No dollar value was put on the three-year agreement, which calls for Sequenom and its subsidiaries to purchase sequencing equipment and consumables from Illumina. The goal is to develop a noninvasive way to detect an overabundance of chromosome 21 in pregnant women, a possible sign of Down syndrome in the fetus. The two San Diego firms say they will collaborate to seek regulatory approval.

Tom Abate is a freelance writer in the San Francisco Bay Area who has covered science, high-tech, biotech, and economics. Follow @

By posting a comment, you agree to our terms and conditions.